Physician profile
Kelly Ledermann
NPI 1942362215
$8,615.11
in general payments reported to CMS, 2019-2025
28 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $801 · 2022: $1,308 · 2023: $2,060 · 2024: $2,579 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,016 · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,015.94 |
| Education | $491.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,445.54 | 2021-2025 | |
| Janssen Biotech, INC. | $1,096.34 | 2021-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $731.64 | 2021-2025 | |
| Genzyme Corporation | $714.84 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $665.63 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $520.74 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $517.59 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $428.71 | 2021-2025 | |
| Dermavant Sciences, INC. | $385.76 | 2023-2024 | Vtama |
| Incyte Corporation | $310.99 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $251.91 | 2021-2025 | Dysport, Nemluvio, Oracea |
| Sun Pharmaceutical Industries INC. | $250.06 | 2021-2024 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $234.58 | 2021-2025 | Dupixent |
| Amgen INC. | $230.06 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $174.78 | 2021-2025 | Anzupgo, Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.07 | 2023-2024 | Spevigo, Cyltezo |
| Ucb, INC. | $91.40 | 2023-2024 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Organon LLC | $60.98 | 2025 | Vtama |
| Journey Medical Corporation | $58.31 | 2022-2023 | |
| Dermira, INC. | $52.40 | 2021 | |
| Allergan, INC. | $47.00 | 2022 | |
| Mission Pharmacal Company | $30.80 | 2021-2022 | |
| Blueprint Medicines Corporation | $25.79 | 2023 | Ayvakit |
| Verrica Pharmaceuticals INC. | $21.14 | 2024 | Ycanth |
| Revance Therapeutics, INC. | $19.32 | 2025 | Daxxify |
| Merz North America, INC. | $18.55 | 2023 | Xeomin |
| Botanix Sb INC | $15.18 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Ledermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.